Solchemia provides custom synthesis of linkers for antibody-drug conjugates (ADCs) — precisely tailored to the unique demands of your therapeutic program. Our expertise encompasses cleavable and non-cleavable designs, including hydrazones, disulfides, peptides, and PEG-based linkers, ensuring optimal stability, biocompatibility, and controlled drug release.
We engineer attachment sites for versatile conjugation strategies such as thiol-, amine-, maleimide-, and click chemistry groups, and offer spacers like PEG chains, alkyl linkers, and amino acid-based tethers to fine-tune pharmacokinetics and solubility. Our peptide chains, including valine–citrulline or glutamic acid–linker systems, enable selective cleavage in target environments, while our payload capabilities span potent cytotoxins such as auristatins, maytansinoids, and camptothecin derivatives.
We deliver high-purity linkers with complete analytical documentation and characterization (including HPLC, NMR, and mass spectrometry), ensuring full traceability and reproducibility. Our scalable processes—from milligram to gram quantities—support both early discovery and preclinical development needs.
Whether you need a well-established structure or a fully novel linker concept, Solchemia provides fast, reliable, and flexible solutions to accelerate your ADC development. Contact us today to discuss your project or request a custom quote.
